摘要
先天免疫和适应性免疫都涉及前列腺癌的发生和发展。在这种情况下,一些治疗的方法已经被提出,目前在前列腺癌患者中正在被广泛的调查。在新兴的免疫目标中,免疫抑制剂监测点如抗细胞毒性T 淋巴细胞蛋白4(CTLA-4),抗程序性死亡因子1(PD-1)和死亡配体1(PD-L1)似乎伴随着溶瘤病毒和疫苗的单独或组合使用方案,为这些病人表达了着最有前景的候选者。在这篇综述中,我们针对患有PCa的患者,更专注于新兴的免疫治疗方法,联合目前的标准治疗包括抗雄激素药物相关性,化疗或放射治疗,显示出了它的合理性。
关键词: 免疫治疗;程序性死亡;预后,前列腺癌;疫苗。
图形摘要
Current Drug Targets
Title:Emerging Immunotargets and Immunotherapies in Prostate Cancer
Volume: 17 Issue: 7
Author(s): Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana and Holger Moch, Rossana Berardi, Marina Scarpelli
Affiliation:
关键词: 免疫治疗;程序性死亡;预后,前列腺癌;疫苗。
摘要: Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Export Options
About this article
Cite this article as:
Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana and Holger Moch, Rossana Berardi, Marina Scarpelli , Emerging Immunotargets and Immunotherapies in Prostate Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160217123304
DOI https://dx.doi.org/10.2174/1389450117666160217123304 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Current Drug Targets Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
Current Pharmaceutical Biotechnology Tannic Acid Inhibits Proliferation, Migration, Invasion of Prostate Cancer and Modulates Drug Metabolizing and Antioxidant Enzymes
Anti-Cancer Agents in Medicinal Chemistry Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy
Current Cancer Drug Targets Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Heart Failure in the Middle East
Current Cardiology Reviews Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry